Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Oct 1;37(5):457-465.
doi: 10.1097/MOP.0000000000001489. Epub 2025 Jul 30.

The evolving landscape of pediatric hepatology: key updates and future directions

Paul Lu  1 , Nadia Ovchinsky  2 , Dana Goldner  2
Affiliations
Review

The evolving landscape of pediatric hepatology: key updates and future directions

Paul Lu et al. Curr Opin Pediatr. .

Abstract

Purpose of review: To provide an update of recent advancements in pediatric hepatology, highlighting new diagnostic criteria, emerging therapeutic options, and molecular insights into liver diseases which are reshaping clinical practice and guiding future research.

Recent findings: Nonalcoholic fatty liver disease (NAFLD) has been redefned as metabolic dysfunction-associated steatotic liver disease (MASLD), reflecting an improved understanding of its underlying pathophysiology. Advances in immunophenotyping have identified activated T-cell hepatitis as a significant contributor to indeterminate pediatric acute liver failure. Additionally, the introduction of ileal bile acid transporter (IBAT) inhibitors marks a transformative shift in the management of pediatric cholestatic diseases including Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC), offering improved growth, quality of life, and native liver survival.

Summary: Recent developments in pediatric hepatology are changing how liver diseases are approached in clinical practice. Evolving disease classifications, expanded use of genetic and immunologic profiling, and the introduction of novel therapies mark a shift toward more individualized care. Ongoing research is needed to evaluate long-term outcomes and ensure that these advances translate into durable improvements for children with liver disease.

Keywords: activated T-cell hepatitis; genetic cholestatic liver disease; metabolic dysfunction-associated steatotic liver disease.

PubMed Disclaimer

References

    1. Vos MB, Abrams SH, Barlow SE, et al. NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr 2017; 64:319–334.
    1. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol 2024; 29:101133.
    1. Rinella ME, Sookoian S. From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease. J Lipid Res 2024; 65:100485.
    1. Li Y, Yang P, Ye J, et al. Updated mechanisms of MASLD pathogenesis. Lipids Health Dis 2024; 23:117.
    1. Pei Y, Goh GB. Genetic risk factors for metabolic dysfunction-associated steatotic liver disease. Gut Liver 19:8–18.